Cleveland Diagnostics Appoints Rich Ramko to Board of Directors
Seasoned life sciences financial advisor brings over 30 years of industry expertise to Cleveland Diagnostics at pivotal time of growth
Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, has appointed Rich Ramko to its Board of Directors. Ramko's extensive financial leadership across the biotech, pharmaceutical, medical device, and healthcare sectors will help support Cleveland Diagnostics as it advances commercialization of its IsoPSA® prostate cancer test and expands its proprietary IsoClear™ platform into new therapeutic areas.
Ramko draws on more than three decades of providing strategic and financial guidance to life science leaders, spanning large publicly held multi-national corporations to venture-backed start-ups. Rich served as U.S. Life Sciences & Healthcare Assurance Leader at Ernst & Young and on EY’s US and Global Life Sciences Boards, which track and analyze market trends to understand their impact on the industry, resource allocation, and investment opportunities.
“I've spent a lot of years watching life sciences companies navigate critical inflection points such as these,” said Ramko. “Cleveland Diagnostics has a very unique structure-based approach to diagnostics, and I'm looking forward to contributing as the company moves further into commercialization.”
